miDiagnostics wants to bring miniaturized, rapid, easy-to-use, lab-quality tests with built in connectivity direct to the patient and clinician.
To do this, we are working to transform attitudes to diagnostic testing, currently dominated by centralised laboratory testing, and provide accurate and integrated disease analysis, enabling rapid access to lab-quality diagnostic information for everyone, anywhere and anytime.
Cameras and chip processors built in our smartphones currently exist of billions of transistors. We apply the power of massive parallelization and miniaturization to microfluidics: many fluidic handling steps occur in parallel at a very small scale resulting in very fast turnaround times.
A key strength of semiconductor technologies is the diversity of nanofluidic processors that can be produced on a single manufacturing platform. This level of mass customization is still unprecedented in high-volume manufacturing industries. We have designed various nanofluidic processors that fit on the same platform for applications in cytology, molecular diagnostics, clinical chemistry and immunoassays, or a combination of these.
An outstanding characteristic of silicon micromachining is the precise control of features at the sub-micron level. We take advantage of this property to create disposable test cards that have the quality and accuracy of lab-based tests.
We are developing three nanoFluidic Processors to measure and quantify cells, nucleic acids, proteins and small molecules
They form the basis for a variety of test cards to diagnose specific medical conditions, such as early screening and treatment of infectious diseases (eg. HPV, GBS, and HIV/HCV/HBV), rapid diagnosis of acute diseases (eg. viral versus bacterial infection, meningitis, and upper and lower respiratory tract infection), and home monitoring of patients (eg. HIV treatment efficacy, organ transplant CMV infection, and chemotherapy monitoring). Our miniaturized, easy-to-use, portable tests deliver lab-quality results directly to patients, clinicians and other non-clinical professionals via their compatible devices within 15 minutes.
Embedded with silicon chip
Analyzes drops of blood
Reads the test card
Connects via USB cable
Processing & computation
Less than 15 minutes to results
Globally Shifting Healthcare
Nicolas Vergauwe joined miDiagnostics as Chief Executive Officer in April 2018. Nicolas and his team are developing and extending the miDiagnostics product portfolio by building on the groundbreaking research of Imec and Johns Hopkins University.
Until March 2018, Nicolas was Vice President Innovations at Biocartis, a molecular diagnostics company that has developed a sample-to-result platform for oncology and infectious disease applications. As VP Innovations,
Nicolas was responsible for bringing novel technologies and assay concepts to the market. Prior to this, he worked at Biocartis as a scientist, joining in January 2012 after obtaining his PhD in Bioscience Engineering at the Katholieke Universiteit Leuven, Belgium.
Alexander joined miDiagnostics as Chief Financial Officer in September 2019, having previously been CFO of an investment holding with €300m of assets under management.
Alexander brings 8 years’ experience as investment manager and CFO of various companies in capex intensive industries in which he completed numerous acquisitions, equity raises and financings. Alexander started his career as a strategy consultant at McKinsey&Co where he focused on M&A and private equity topics across a wide range of industries and geographies.
He obtained a MSc in Business Engineering from the KULeuven and a MSc in Finance from the London School of Economics.
Prior to joining miDiagnostics, Peter was a professor of electrical engineering at Stanford University where his work focused on large area electronics, solar energy conversion and biomedical electronics.
Peter is the Company’s CTO, having initiated imec’s research program into silicon fluidics-based point-of-care diagnostics and helping to found miDiagnostics in 2015.
He currently also holds the role of CTO Health Technologies at imec.
Peter holds a Ph.D. in electrical engineering from Princeton University, and a bachelor’s and master’s degree in engineering from the Katholieke Universiteit Leuven. He is the recipient of and NSF career award and a Belgian-American Educational Foundation honorary fellowship.
Ben joined the miDiagnostics team as Director Quality and Regulatory Affairs in February 2019.
He is responsible for the development and execution of the Regulatory and Quality Strategies for miDiagnostics and its product platform.
Ben has worked in various operations, regulatory and research roles within the pharmaceutical and medical device industries for over 25 years, with companies such as Merck, Johnson & Johnson Medical, Ethicon, LifeScan, and DePuy.
During his career, Ben has had leadership positions within Project Management, Quality Assurance, Operations, Regulatory Affairs and R&D. During this time, Ben collaborated in and led a variety of product approvals, process improvements, process introductions and product launches. This has included the direction of activities across Europe, the USA and the Far East.
Ben has a BSc in Biochemistry from the University of Nottingham and a Post Graduate Diploma in Management from the University of Bradford.
Christopher Adams joined miDiagnostics in September 2019. He has extensive experience in translating products from early inception to product launch, particularly within the diagnostics industry.
Before joining miDiagnostics, Christopher served for 7 years as Head of Biotechnology and Innovation at QuantuMDx. Christopher holds a PhD in Physics from the University of Glasgow.
Board of directors
Dr. Rudi Pauwels is a scientist-entrepreneur with a background in pharmacy, diagnosis and virology.
In an effort to meet current and future medical needs through innovative breakthrough approaches, he has (co)founded several successful biotechnology companies over the past three decades.
These companies and their products marked the new era of high-precision personalized medicine.
With his colleagues, he developed several anti-HIV drugs (Prezista®, Intelence®, Edurant®) used by patients around the world (Tibotec).
In the late 1990s, his innovative diagnostic methods also led to the selection of optimal ANTI-HIV regimens for each patient (Virco).
Over the past decade, as founder and CEO of Biocartis, he has focused on developing new, high-quality molecular diagnostic solutions that are patient-friendly.
In 2017, he decided to relinquish his position as CEO of Biocartis in order to focus more on his interests in infectious diseases and technological innovation.
He became involved in social entrepreneurship by creating the Praesens Foundation.
At the same time, he is a member of the investment committee of Smile Invest, a fund that invests in growing companies, as well as the Singapore government’s Innovation Advisory Board, A*STAR.
He is also a member of the Scientific Board of IMEC and chairs the board of directors of miDiagnostics.
Dr. Pauwels has received several awards for excellence and scientific and entrepreneurial achievements.
In 2012, his company Biocartis received the Global Technology Pioneer Award from the World Economic Forum (Davos, Switzerland).
He received an honorary doctorate from the University of Ghent in 2013. In 2016, he was named an honorary speaker at the Distinguished Technopreneur Speaker (DTS) forum in Singapore.
In July 2016, the King of Belgium awarded him the title of “Commander of the Order of Leopold”.
He is (co) author of more than 150 articles in peer-reviewed journals. Dr. Pauwels holds a Ph.D. in Pharmaceutical Sciences from The Katholieke Universiteit Leuven, Belgium
Dr. Urbain Vandeurzen is the founder and chairman of Smile Invest ,a large new private equity fund with 350 M euros equity for innovative growth companies funded by a group of successful entrepreneurs and wealthy families in the Benelux.
In 1980, Urbain Vandeurzen was a co-founder of high-tech company LMS International, where he took up the role of chairman and CEO until he successfully sold it to Siemens in 2013. LMS has become the worldwide innovation partner for the Top 500 companies in the automotive, aerospace and other high tech manufacturing companies.
Since the start in 2014, he became the chairman of the new Strategic Research Center of Manufacturing Industry, Flanders Make. He was also the founder and the chairman of Flanders Drive in 1996. Since 2012, he has been a member of the board of directors at KU Leuven and became chairman of the KULeuven “Opening the Future” fundraising campaign. Since 2016, he is chairman of Mission Lucidity a strategic research initiative of KULeuven, VIB, imec and UZ Gasthuisberg for decoding dementia.
Furthermore, since 2013, Urbain Vandeurzen has played a leading role in the transformation of the local economy in Limburg as president of the Entrepreneurs Platform Limburg (OPL and the Limburg Innovation Center (Limburgs Innovatiecentrum).
In addition, he has been the Chairman of the Board of Directors of VOKA-Vlaams Economisch Verbond, the Employers organisation in Flanders from 2006 to 2009, of which he is now Honorary Chairman He has also served as Vice-Chairman of the Federation of Enterprises (VBO) in Belgium, Vice-Chairman of Agoria Flanders and Vice-Chairman of the Leuven Chamber of Commerce, and he was the chairman of the board of directors of Gimv NV from 2011 until 2016.
In addition, He is currently a director in a number of technology, industrial and financial services companies.
He was a director of Barco, of Van Breda Risk and Benefits, chairman on the board of directors of Scia,. Furthermore, he is been involved in educational reform and innovation policy in Flanders as chairman of the “Focus on Talent” committee of the King Baudouin Foundation and the Fund for Scientific Research (FWO). As chairman of VOKA-VEV, he was also deeply involved in defining the “Flanders in Action” transformation programme.
Marc Coucke founded Omega Pharma in 1987 and under his leadership the firm grew both organically and externally into a leading European OTC pharmaceuticals company. In 2015, Omega Pharma was acquired by Perrigo where Mr. Coucke today serves as Executive Vice President and General Manager, Perrigo-Omega Pharma. In addition to this, Mr. Coucke is a member of the Board of Perrigo. Through Alychlo NV, Mr. Coucke acts as a serial entrepreneur investing in funds and in fast-growing (Belgian) enterprises. Mr. Coucke graduated as a Qualified Pharmacist from the State University of Ghent, Belgium, and holds an MBA from the Vlerick Business School, Ghent, Belgium
Luc Van den hove is President and Chief Executive Officer (CEO) of imec since July 1st, 2009. Before holding this position, he was Executive Vice President and Chief Operating Officer. He joined imec in 1984.
Under his guidance imec has grown to an organization with a staff of around 4000 people, operating with an annual budget of around 640M€ (2019) and with offices in Belgium, the Netherlands, US, Japan, Taiwan, China and India.
Currently, Luc Van den hove is also professor of Electrical Engineering at the University of Leuven. He is also a member of the Technology Strategy Committee of ASML.
He has authored or co-authored more than 150 publications and conference contributions. He is a frequently solicited speaker on technology trends and applications for nano-electronics at major top conferences. He has presented more than 50 key note presentations.
Luc Van den hove received his Ph.D. in Electrical Engineering from the University of Leuven, Belgium.
Pieter Bourgeois is an Investment Manager at Alychlo NV, the investment firm of Belgian entrepreneur Marc Coucke. Prior to this, Mr. Bourgeois worked in different financial roles focusing on M&A and strategic projects, gaining business acumen in a variety of sectors and different sizes of companies. Mr. Bourgeois holds a Masters Degree in Industrial Engineering and is an MBA from the Solvay Brussels School of Economics & Management.
Michel Akkermans is a serial entrepreneur, private investor, advisor and board member, serving on the boards of public and private companies and private equity funds. For a complete list, please refer to www.pamica.be.
He was co-founder, Chairman and CEO of Clear2Pay, a finance technology company focused on global payment solutions, before it was acquired by FIS (Nasdaq: FIS) in 2014. Before Clear2Pay, Mr. Akkermans was founder, CEO and Chairman of FICS, a fintech company specialized in online banking and compliance reporting. In 1999, FICS merged with Security First Technologies, creating the leader in Internet banking – S1 Corporation (Nasdaq: SONE), with Mr. Akkermans as its chairman. He also was executive chairman of Data4S, a data analytics specialist, focusing on anti-money laundering applications. Norkom acquired the company in 2004. Clear2Pay, FICS and Data4S generated superior returns for their investors and management teams.
Mr. Akkermans holds a M.S. in electronic engineering and computer sciences and a degree in economics and finance from the University of Leuven, Belgium.
Mr. Verhaeghe represents major European, American and Asian multinationals and medium-size enterprises and start-ups in all sectors of the economy. He has significant corporate, corporate finance and tax experience in advising clients on the establishment and functioning of holding and trade companies as well as distribution and service centers in Europe.
In addition, Mr. Verhaeghe has represented over the years several media and entertainment groups, as well as numerous biotech and pharmaceutical companies as well as hi-tech/software companies with respect to their intellectual property rights and the legal and tax aspects of their financing needs.
Mr. Peter Verhaeghe is a past Member of the Board of Directors of Tibotec-Virco NV (Belgium), Innogenetics NV (Belgium), KBC Private Equity Biotech (Belgium), and Bever Zwerfsport Investments BV (The Netherlands), PharmaNeuroBoost NV (Belgium) and Biocartis SA (Switzerland). He has also been a Board member and thereafter the liquidator of KBC Private Equity Biotech NV, a Euronext listed biotech fund, and member of the Board of Directors of Merisant Company 2 sàrl (Switzerland) and CzechPak Manufacturing sro (Czech Republic) as well as Chairman of Merisant France SAS (France).
Next to being a member of the Board of Directors of miDiagnostics NV, Mr. Verhaeghe is currently also Chairman of the Board of argenx SE (the Netherlands), a Euronext and NASDAQ listed company, Member of the Board of Directors of Participatiemaatschappij Vlaanderen (PMV) (Belgium) and Chairman of the Board of Directors of Haretis SA (Luxembourg)
miDiagnostics Raises €14m to Accelerate the Commercialization of its Disruptive, Lab-quality Silicon Chip Diagnostics Platform
Supported by existing shareholders and new investors, including tech entrepreneur Urbain Vandeurzen and life sciences entrepreneur Rudi Pauwels Technology has potential to deliver rapid test
Leuven, Belgium – January 2020 – While new solutions for health are emerging in different parts of the world, these do not always get adopted
miDiagnostics’ disposable blood testing device to be evaluated by imec for use in zero gravity environments
Leuven (BELGIUM) and Kissimmee (FLORIDA), Nov. 19 2019 – Today, imec, a world-leading research and innovation hub in nano-electronics and digital technologies announced it has
miDiagnostics has agreed a partnership with Notified Body, BSI (the Netherlands) to assess and certify the miDiagnostics Quality Systems to ISO 13485 (2016) in preparation for the CE marking and 510(k) clearance.
For miDiagnostics being a member of Leuven MindGate allows to be informed about and receive access to exclusive Leuven MindGate member activities and content.